Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent

Authors: Firpi, R. J.; Tran, T. T.; Flores, P.; Nissen, N.; Colquhoun, S.; Shackleton, C.; Martin, P.; Vierling, J. M.; Poordad, F. F.

Source: Alimentary Pharmacology & Therapeutics, Volume 19, Number 9, May 2004 , pp. 1033-1039(7)

Publisher: Wiley-Blackwell

Buy & download fulltext article:

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

Summary Background

: Sirolimus is a potent immunosuppressive medication that acts by inhibiting T-cell proliferation. It has been used in kidney transplantation because of its lack of nephrotoxicity. It is now being investigated in liver transplantation, but there are concerns about safety and long-term side effects such as dyslipidaemia. Hypertriglyceridaemia is a common adverse event seen with sirolimus use, and often does not respond to dose reduction or anti-lipemic drugs. Method

: We report six patients who have developed significant hyperlipidaemia while receiving sirolimus, in spite of therapeutic trough levels. Conclusion

: All six patients showed either resolution or improvement in lipid levels with discontinuation of sirolimus.

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2036.2004.01923.x

Publication date: 2004-05-01